Kinlock Timothy W, Gordon Michael S, Schwartz Robert P, Fitzgerald Terrence T
Friends Research Institute, Inc.
J Offender Rehabil. 2010 Feb;49(2):91-109. doi: 10.1080/10509670903534951.
Research suggests that buprenorphine treatment may be a promising intervention for incarcerated individuals with heroin addiction histories. However, its implementation varies from corrections-based methadone because of unique challenges regarding dosing, administration, and regulation. Describing the first randomized clinical trial of prison-initiated buprenorphine treatment in the United States, this manuscript focuses on how these obstacles were overcome through collaboration among correctional, treatment, and research personnel. Building on the present authors' work in developing prison-based methadone treatment, and considering the lack of experience in implementing corrections-based buprenorphine programs in the United States, this manuscript may serve as a guide for interested corrections officials, treatment providers, and researchers.
研究表明,丁丙诺啡治疗对于有海洛因成瘾史的被监禁者可能是一种有前景的干预措施。然而,由于在剂量、给药和监管方面存在独特挑战,其实施与基于惩教机构的美沙酮治疗有所不同。本文描述了美国首次由监狱发起的丁丙诺啡治疗随机临床试验,重点关注如何通过惩教人员、治疗人员和研究人员之间的合作克服这些障碍。基于本文作者在开展基于监狱的美沙酮治疗方面的工作,并考虑到美国在实施基于惩教机构的丁丙诺啡项目方面缺乏经验,本文可作为感兴趣的惩教官员、治疗提供者和研究人员的指南。